[{"id":"b7e56290-6b1a-48dc-8f8b-3b38875c7932","acronym":"GENUINE","url":"https://clinicaltrials.gov/study/NCT05286060","created_at":"2022-03-18T12:53:37.680Z","updated_at":"2024-07-02T16:34:26.476Z","phase":"Phase 2","brief_title":"Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer","source_id_and_acronym":"NCT05286060 - GENUINE","lead_sponsor":"Yonsei University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-13"},{"id":"9d871764-105a-4f58-865b-c37055f88db6","acronym":"KEYNOTE-567","url":"https://clinicaltrials.gov/study/NCT03444376","created_at":"2021-01-18T16:59:06.658Z","updated_at":"2025-02-25T16:07:36.275Z","phase":"Phase 1/2","brief_title":"The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer","source_id_and_acronym":"NCT03444376 - KEYNOTE-567","lead_sponsor":"Genexine, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 04/29/2022","primary_completion_date":" 04/29/2022","study_txt":" Completion: 12/21/2023","study_completion_date":" 12/21/2023","last_update_posted":"2024-03-01"},{"id":"21f8bb16-844c-42fc-ae99-b94057a6b65f","acronym":"TRINITY","url":"https://clinicaltrials.gov/study/NCT05280457","created_at":"2022-03-15T18:52:58.634Z","updated_at":"2024-07-02T16:35:52.113Z","phase":"Phase 2","brief_title":"HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy","source_id_and_acronym":"NCT05280457 - TRINITY","lead_sponsor":"Yonsei University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-03-28"}]